Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body, most commonly originating from the lungs and gastrointestinal tract. Lung NETs can be classified as well differentiated (low-grade typical carcinoids [TCs] and intermediate-grade atypical carcinoids [ACs]) and poorly differentiated (high-grade large cell neuroendocrine carcinoma or SCLC). The incidence of these tumors is increasing, but disease awareness remains low among thoracic specialists, who are often involved in the diagnosis and early treatment for these patients. An accurate and timely diagnosis can ensure the implementation of appropriate treatment and have a substantial impact on prognosis. However, lung NET classification and diagnosis, particularly for TCs/ACs, are complicated by several factors, including a variable natural history and nonspecific symptoms. Surgery remains the only curative option for TCs/ACs, but there is a lack of consensus between lung NET management guidelines regarding optimal treatment approaches in the unresectable/metastatic setting on account of the limited availability of high-level clinical evidence. As a result, a multidisciplinary approach to management of lung NETs is required to ensure a consistent and optimal level of care. RADIANT-4 is the first phase III trial involving a large subpopulation of patients with advanced well-differentiated lung NETs to report reductions in the risk for disease progression and death with everolimus over placebo. This led to the recent U.S. approval of everolimus-the first agent approved for advanced lung TCs/ACs. To further improve evidencebased care, additional randomized controlled trials in patients with lung carcinoids are needed. 
Introduction
Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body and most commonly originate from the lungs, small intestine, and rectum. 1 Lung NETs originate from pulmonary neuroendocrine cells (PNECs) that occur as individual cells or small PNEC clusters (neuroepithelial bodies), 2 accounting for approximately 25% of primary lung neoplasms.
prostate, and other locations; in these organs, the term carcinoid has been replaced by well-differentiated NETs. 5 In the United States, the annual incidence of lung NETs has substantially increased over the past 30 years, rising from 0.3 cases per 100,000 in 1973 to 1.35 cases per 100,000 in 2004. 1 Improvements in detection methods and diagnostic protocols are likely a major contributor to this observed increase in cases of lung NET. 6 Historically, there have been limited clinical data available regarding lung NETs, particularly for carcinoid tumors (TCs and ACs), thus making diagnosis and treatment challenging. Despite the increasing incidence, awareness of lung NETs is relatively low among thoracic surgeons, oncologists, pathologists, and pulmonary care physicians, who are often involved in the diagnosis and early treatment for these patients. Therefore, this article will highlight and address the current challenges and findings of key clinical trial in lung NETs while emphasizing the importance of establishing a multidisciplinary approach in the diagnosis and treatment of patients with lung NETs, with a focus on TCs and ACs.
Disease Overview

Etiology
Although lung NETs are considered a distinct family of tumors with shared morphologic, ultrastructural, immunohistochemical, and molecular characteristics, 4 there is evidence to suggest that TCs and ACs are morphologically distinct from LCNECs and SCLCs. 7 Mechanisms for the development and progression of well-differentiated lung NETs are unclear. Most TCs and ACs arise de novo, although they would be classified as carcinoid tumorlets if discovered when they measure 5 mm or less. 4 However some TCs and ACs develop in patients with diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH), a rare preneoplastic lesion characterized by the association of preinvasive hyperplasia of PNECs and neuroepithelial bodies in the respiratory epithelium and multiple carcinoid tumorlets. 4, [8] [9] [10] [11] A recent study has proposed the presence of PNEC hyperplasia in at least three bronchioles associated with three or more tumorlets as the minimum pathologic criteria necessary to diagnose DIPNECH in pathologic specimens. 12 Although poorly differentiated lung NETs (e.g., SCLCs) have a strong association with smoking, there does not appear to be a relationship between welldifferentiated lung NETs and smoking, with TCs and ACs often occurring in nonsmokers. 3 Approximately 5% of cases of TC and AC are associated with multiple endocrine neoplasia type 1 (MEN-1). 13 There is no association between poorly differentiated lung NETs and DIPNECH. 9 
Epidemiology
Well-differentiated lung NETs comprise approximately 27% of all NETs 1, 14 and 1% to 2% of all primary lung cancers, 3, 13 with estimated age-adjusted incidence rates of 0.2 to two cases per 100,000 in the United States and Europe. 15 Although rare, the prevalence of welldifferentiated lung NET has increased by approximately 6% per year over the last 30 years in both men and women. 14, 16 In contrast, a decreasing trend in SCLC incidence has been observed. 4 TCs are more prevalent than ACs, accounting for approximately 90% of welldifferentiated lung NET. 3 
Diagnosis and Classification
The presence of a tumor in the lung is often suspected only when initial treatment fails to improve symptoms, 7 thus delaying diagnosis. A recent global survey (n ¼ 1928) collected data on NETs from a patient perspective. 17 Of the 222 patients with lung NETs who participated in the survey, 50% reported a period of up to 2 years from their first symptom to a diagnosis of lung NET; in 49%, other conditions were previously diagnosed. 17 These findings highlight the potential for substantial delays in achieving an accurate lung NET diagnosis.
Although TCs and ACs are considered low-or intermediate-grade tumors, they are capable of regional lymph node or distant metastasis, which affects prognosis. From 5% to 20% of TCs and 30% to 40% of ACs metastasize, with many patients presenting with recurrent disease or metastases to the liver or bone. 18 As a result, delays in diagnosis increase the probability of metastatic disease, which has a negative impact on prognosis. 1, 14, 19 
Clinical Presentation
Many patients with lung NETs are asymptomatic at the time of diagnosis 20 or present with nonspecific symptoms that often mimic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease), thus complicating diagnosis. 21 Most well-differentiated lung NETs are located centrally in the main (10%) or lobar bronchi (75%), with the remainder located in the peripheral lung. 3, 4, 6, 16 As a result, symptoms usually reflect tumor location, with centrally located tumors (primarily TCs) often presenting with obstructive respiratory symptoms related to tumor mass, including cough, hemoptysis, dyspnea, chest pain, wheezing, and pneumonitis. 6, 15, 16, 22 In contrast, peripherally located tumors (typically ACs) usually present as asymptomatic incidental findings. 6, 20 Although more than 90% of lung NETs are nonfunctional, 23 patients with functional (secretory) lung NETs may present with hormonal symptoms (i.e., wheezing, cutaneous flushing, and diarrhea) owing to tumor cell secretion of hormones and peptides, such as serotonin. 16 Bronchopulmonary carcinoids occur in 5% to 8% of patients with MEN-1. 24, 25 Pulmonary carcinoids in MEN-1 may be underreported and research on their natural history is limited, but disease-related mortality in this group is low compared with that in patients with thymic carcinoid. 25 When MEN-1 is suspected, patients should be referred to genetic counseling for germline testing.
Classification by Histologic Subtype
Histologic classification according to the WHO and tumor staging according to the American Joint Committee on Cancer/International Association for the Study of Lung Cancer TNM staging system has the highest impact on prognosis and treatment of lung NETs. 26 A recent 2015 update of the WHO classification of lung tumors provided diagnostic criteria for lung NETs on the basis of histopathologic features, including cell size, cell morphologic features, mitotic index, architectural growth patterns, and presence of necrosis. 4 This update groups all four histologic variants of lung NETs (TCs, ACs, LCNECs, and SCLCs) into one category to facilitate differential diagnosis, 4 whereas carcinoids were grouped separately from LCNECs and SCLCs in the 2004 WHO classification. [27] [28] [29] LCNECs and SCLCs are classified as having a high tumor grade, whereas welldifferentiated lung NETs can be classified as having either a low (TCs) or intermediate (ACs) tumor grade. 4, 8 The two key characteristics that aid in the differentiation of lung NET subtypes are the presence or absence of necrosis and the number of mitoses per 2 mm 2 of viable area of tumor 4 ; this mitosis counting method was changed from the 2004 recommendation of counting the number of mitoses per 10 high-power fields. 27, 29 TCs are defined as lung carcinoid tumors measuring at least 0.5 cm, with fewer than two mitoses per 2 mm 2 of viable area of tumor and lacking necrosis, whereas ACs have two to 10 mitoses per 2 mm 2 of viable area of tumor, with the presence of necroses that are often focal (Fig. 1) . 4, 8 The updated 2015 WHO classification for lung NETs also provides guidance on use of the Ki-67 cell proliferation labeling index to distinguish between high-grade lung NETs (>40%) and carcinoids (<20%) (Fig. 2) , 4, 30 particularly in crushed biopsy specimens, in which carcinoids may be mistaken for SCLCs. 31 However, overlap in the distribution of Ki-67 labeling index between TCs (5%) and ACs (20%) does not allow Ki-67 expression to reliably distinguish between well-differentiated lung carcinoids. 4, 15, 29, 30, 32 The utility of Ki-67 to differentiate between TCs and ACs has yet to be established and it is not presently recommended. 4, 29, 32 The histopathologic differences between pulmonary NETs can be subtle, particularly in small biopsy specimens or cytologic samples. This can give rise to substantial interobserver variability among pathologists with regard to the distinction between TCs and ACs and, less often, overdiagnosis of SCLC in some patients with carcinoid tumors. 15, 31, 33 This complicates the ability to accurately classify patients with pulmonary NETs, which potentially affects selection of appropriate treatment and ultimately patient prognosis.
15,32
Grading
The diagnostic terminology and criteria used for the identification of various neuroendocrine neoplasms is somewhat variable for tumors arising in the lung, GI tract, and other organs, as already explained. Different cutoffs are used to evaluate mitotic activity in pulmonary and GI neuroendocrine neoplasms; proliferative index as measured with Ki-67 immunohistochemistry is an integral part of the current classification of GI neuroendocrine neoplasms, whereas Ki-67 indices overlap in lung NET subtypes. 4, 29, 32 Interestingly, cellular differentiation and cytologic atypia do not correlate well with prognosis in patients with neuroendocrine neoplasms, regardless of the tumor origin.
A grading schema that classifies lung NETs as grade 1 (TCs), grade 2 (ACs), and grade 3 (SCLCs and LCNECs) is very helpful in guiding therapy. Patients with grade 1 or 2 tumors are generally treated with somatostatin analogues (SSAs) and other drugs described later, whereas patients with grade 3 tumors are treated with chemotherapy.
Proliferative index measured by Ki-67 labeling is not currently used for the grading of lung NETs, but as it has been shown to be a significant prognostic feature, the inclusion of this information in addition to tumor grade may help oncologists to individualize patient treatment.
4,15,29
Staging Criteria
Although not specific to lung NETs, the American Joint Committee on Cancer/International Association for the Study of Lung Cancer TNM staging system for non-NET lung cancers may be utilized, 4, 32 and TNM staging of TCs and ACs has been shown to be prognostic for survival. 34 Both TCs and ACs are capable of regional lymph node or distant metastasis, 35, 36 with ACs being more aggressive than TCs. In a large multiinstitutional study, ACs had higher rates of lymph node involvement at diagnosis (36%) and distant metastases (26%) than TCs (9% and 4%, respectively), highlighting the importance of long-term follow-up in patients with lung carcinoids, including those with low-grade tumors. 35 Furthermore, ACs are associated with poorer 5-and 10-year survival rates than TCs. 35, 37 Despite the prognostic role of TNM staging for TCs and ACs, the utility of this system for staging lung carcinoids using the predefined cutoff values of 3, 5, and 7 cm has been questioned given that TCs and ACs are often smaller than 3 cm in their largest diameter. 32 
Additional Assessments
WHO classification recommends the detection of immunohistochemical markers to confirm a diagnosis of lung NET, with chromogranin A, synaptophysin, and CD56 included. 4, 16 However, these tumor markers are not able to distinguish between subtypes of lung NETs. 4 Tumor expression of thyroid transcription factor-1 may also be utilized to confirm a diagnosis of lung NET, but most TCs and ACs are negative for this marker. Imaging techniques also play an important role in the identification of key tumor characteristics, lymph node involvement, and the presence of metastases in lung NETs. 16 Computed tomography (CT) is commonly used for NET detection, localization, and staging, 38 and it is recommended for the diagnosis of suspected centrally located lung carcinoids, 15 whereas magnetic resonance imaging is preferred for detecting and characterizing bone or liver metastases. 15, 38 Functional imaging using radiolabeled SSAs has also been shown to be sensitive for the localization of lung carcinoids and detection of metastases, given that most patients with TCs or ACs (approximately 80%-90%) express somatostatin receptors. 6, 16, 22 Positron emission tomography (PET)/CT, single-photon emission tomography/CT, and singlephoton emission tomography/planar somatostatin receptor (SSTR) scintigraphy (e.g., indium 111 pentetreotide, Octreoscan [Mallinckrodt Nuclear Medicine LLC, Maryland Heights, MO] and 68 Ga-DOTATATE/TOC) have been utilized as diagnostic tools in the TC/AC setting. 26, [38] [39] [40] With regard to somatostatin receptor scintigraphy testing, PET using 68 Ga-DOTATATE/TOC is preferable to Octreoscan if available 15 ; it has several advantages over Octreoscan, including the improved spatial resolution and shorter scanning time of PET and the higher binding affinity to SSTR type 2 and favorable pharmacokinetic properties of the radiopeptides. 41 In addition to tumor detection, SSTR imaging provides an estimation of receptor density and evidence of the functionality (internalization capacity) of receptors, providing important information for selection of suitable treatments that act on these receptors, such as SSAs and peptide receptor radionuclide therapy (PRRT). 26, 42 Fludeoxyglucose F-18 PET has shown utility as a radiologic marker for ACs, particularly for ACs with a higher proliferation index (Ki-67 index of 10%-20%), but it is most useful in LCNECs and SCLCs. 15, 26 Finally, bronchoscopy is an invasive procedure that can be used to diagnose the presence of centrally located lung carcinoids, and it enables performance of a biopsy to confirm histologic subtype. 15, 16 Although the diagnostic yield of this approach in clinical practice is unclear, a recent case study reported the successful diagnosis of a peripheral lung carcinoid tumor using endobronchial ultrasoundguided bronchoscopy and transbronchial lung biopsy. 43 
Lack of Consensus between Management Guidelines
A lack of consensus between diagnostic guideline recommendations further complicates the diagnosis of lung NETs. The recently updated the National Comprehensive Cancer Network (NCCN) guidelines on SCLC management provide a list of recommended diagnostic assessments if a TC or AC is suspected upon biopsy, 44 whereas the NCCN guidelines on NETs do not indicate the need for a biopsy when a lung NET is suspected and do not provide clear guidance on evaluation by lung NET subtype (Table 1) . 45 In contrast, European Neuroendocrine Tumor Society (ENETS) guidelines for TCs and ACs provide a detailed algorithm for the diagnosis of suspected TCs or ACs, recommending the use of imaging techniques, histopathologic evaluation, genetic assessment, and assessment of biochemical secretions (Fig. 3) . 15 
Treatment
Localized Disease
Surgical resection is the treatment of choice in patients with localized TCs or ACs, 15, 44, 45 and it is the only curative option for resectable lung carcinoids. After Table 1 . Diagnostic Evaluation/Work-up Guidelines According to the NCCN Guidelines surgical resection, the 5-and 10-year survival rates are both higher than 90% for patients with TCs, whereas patients with AC have a 5-year survival rate of 70% and a 10-year survival rate of 50%. [46] [47] [48] In the adjuvant setting, chemotherapy with or without radiation therapy has not been well studied in lung NETs, and there is a lack of consensus between treatment guidelines. 15, 44, 45 NCCN guidelines for NETs indicate that there is no known role of adjuvant systemic therapy for carcinoid tumors, 45 whereas North American Neuroendocrine Tumor Society guidelines note a lack of evidence to support effective implementation of adjuvant chemotherapy and/or radiation for the treatment of lung NETs. 13 In contrast, NCCN guidelines for SCLC recommend the use of adjuvant cisplatin/etoposide with or without radiation therapy in patients with stage II or III ACs, 44 whereas ENETS guidelines indicate that adjuvant therapy may be considered in patients with ACs with positive lymph nodes; the use of adjuvant therapy is not recommended for TCs. 15 
Advanced/Metastatic Disease
Surgery may also be considered in patients with advanced/metastatic disease, and complete surgical resection of the primary tumor and metastases with curative intent can often be recommended for patients with limited sites of metastatic disease. 15 In addition, an international, multi-institutional analysis reported the efficacy of cytoreductive surgery with or without ablation, particularly in patients with functional hepatic metastasis. 49 However, there is a lack of consensus regarding recommended management approaches for unresectable advanced or metastatic disease owing to the lack of prospective clinical trials that include primarily patients with lung carcinoids. 6, 13, 15, 44, 45, 50 In addition, there is controversy regarding the guidelines' recommendation for asymptomatic patients with advanced carcinoid tumors with a low proliferative index (TCs) and tumor burden to be placed under observation on the basis of regular imaging 15 Figure 3 . Diagnostic evaluation/work-up recommendations according to the European Neuroendocrine Tumor Society guidelines for typical carcinoids (TCs) and atypical carcinoids (ACs). a Accurate echocardiographic evaluation should always be carried out before surgical procedures and at both diagnosis and follow-up to evaluate the presence and evolution of carcinoid heart disease. NET, neuroendocrine tumor; MEN-1, multiple endocrine neoplasia type 1; PTH, parathyroid hormone; CT, computed tomography; 5-HIAA, 5-hydroxyindoleacetic acid; ACTH, adrenocorticotropic hormone; GHRH, growth hormone-releasing hormone; IGF-1, insulin growth factor 1; MRI, magnetic resonance imaging; EBUS, endobronchial ultrasonography; PET, positron emission tomography; FDG-PET, fludeoxyglucose F 18 positron emission tomography. Reprinted from Caplin et al. 15 with permission.
disease treated with SSAs in the CLARINET trial. 51 Systemic treatment options for advanced NETs of all primary tumor sites include SSAs (octreotide and lanreotide), targeted therapy (everolimus, sunitinib, and bevacizumab), interferon, chemotherapy, and PRRT (for SSTR-expressing NETs). 6, 13, 15, 44, 45 The recently updated ENETS guidelines provide guidance on the management of advanced TCs and ACs with systemic therapies, indicating that pathologic features (mitotic count and Ki-67), SSTR expression, and growth rate (slowly or actively progressive) should be taken into consideration ( Table 2) , which is similar to the guidance on gastroenteropancreatic NETs. 15, 50 Despite the lack of comprehensive clinical trial data on SSAs in patients with lung NETs, the NCCN guidelines on NETs and SCLCs recommend the consideration of octreotide or lanreotide for select patients with symptoms of carcinoid syndrome or octreotide-positive scans. 44, 45 ENETS guidelines also indicate that the clinical response of TCs to SSAs is expected to be similar to that of low-grade NETs from other sites, 50 and they recommend the use of SSAs as a first-line option in patients with lung carcinoids exhibiting hormone-related symptoms (carcinoid syndrome or Cushing's syndrome). Furthermore, given that most patients with TCs or ACs (approximately 70%) have a positive SSTR status when assessed by Octreoscan, 52 ENETS guidelines recommend first-line antiproliferative treatment for a slowly progressive TC or AC with a low proliferative index (preferably Ki-67 <10%), provided there is a strongly positive SSTR status. 15, 50 Prospective clinical trials are required to determine the role of SSAs in lung carcinoids.
Studies of cytotoxic chemotherapy regimens in the advanced or metastatic lung carcinoid setting have been limited to small prospective studies or retrospective analyses, and they have yielded minimal, short-lasting activity, particularly for ACs. 13, 18, 18, [53] [54] [55] [56] As a result, a standard chemotherapeutic regimen has not been established. The NCCN guidelines on NETs indicate that cytotoxic chemotherapy (no preferred regimen) for patients with progressive metastases should be considered only when no other treatment options are available. 45 In contrast, cisplatin-etoposide or other cytotoxic regimens (e.g., temozolomide based) are recommended by the NCCN SCLC guidelines for advanced TCs and ACs, with cisplatin-etoposide being the preferred first-line systemic regimen in stage IV AC. 44 Furthermore, the ENETS guidelines state that systemic chemotherapy is generally restricted to ACs after failure of other therapies and only under certain conditions (Ki-67 >15%, rapidly progressive disease, and SSTR-negative disease), 50 and they note that temozolomide monotherapy has shown the most clinical benefit. 15 Capecitabine-temozolomide has recently shown moderate activity in a small, singleinstitution study of patients with advanced lung carcinoids (N ¼ 19), with 11 of 17 assessable patients (65%) demonstrating stable disease or partial response 57 ; however, large, prospective, randomized controlled trials are required to further investigate efficacy.
Until recently, clinical data for targeted therapy in patients with lung NETs have been lacking, particularly in TCs and ACs. The pivotal randomized, placebocontrolled, phase III RADIANT-4 trial (N ¼ 302) recently evaluated the efficacy of the mammalian target of rapamycin inhibitor everolimus (10 mg/d) in adult patients with advanced, well-differentiated, nonfunctional NETs of GI/lung origin who were receiving best supportive care (excluding SSAs). 58 In the overall study population, everolimus prolonged progression-free survival (PFS) by central review (the primary end point) versus placebo (11.0 versus 3.9 months), resulting in a 52% reduction in the risk for disease progression or death that was statistically significant and clinically meaningful (hazard ratio [HR] ¼ 0.48, 95% confidence interval [CI]: 0.35-0.67, p ¼ 0.00001). 58 Numerical improvements in survival favoring everolimus were also observed in the first and 58, 59 Everolimus was generally tolerated in the study, with most adverse events being grade 1 or 2 in severity and manageable with dose modification or interruption. 58 These findings led the ENETS guidelines to recommend everolimus as a first-line therapy for metastatic, progressive lung NETs (Table 2) . 50 The positive RADIANT-4 data also resulted in the recent U.S. Food and Drug Administration (FDA) approval of everolimus for adults with progressive, well-differentiated, nonfunctional NETs of GI or lung origin that are unresectable, locally advanced, or metastatic. 60 To confirm that the PFS benefit seen with everolimus in the overall RADIANT-4 study population was maintained in the lung NET subpopulation (n ¼ 90), a post hoc subgroup analysis was conducted and reported a median PFS by central review favoring everolimus versus placebo (9.2 versus 3.6 months, HR ¼ 0.50, 95% CI: 0.28-0.88). 61 Furthermore, the everolimus safety profile of the RADIANT-4 lung NET subpopulation was similar to that of the overall population, with the most frequently reported adverse events (all grades) observed with everolimus in both the overall population and the lung NET subpopulation being stomatitis (63% and 61%, respectively), diarrhea (31% and 26%), fatigue (31% and 32%), infections (29% and 23%), rash (27% and 35%), and peripheral edema (26% and 27%). 58, 61 On the basis of the recent FDA approval of everolimus for progressive, nonfunctional, well-differentiated lung NETs and the findings of the RADIANT-4 subgroup analysis, it is anticipated that everolimus will be incorporated into future guideline updates as a first-line therapy for progressive, well-differentiated, nonfunctional NETs of lung origin. This makes everolimus the only systemic targeted agent approved for the treatment of advanced or metastatic TCs and ACs, given that bevacizumab, sorafenib, pazopanib, and axitinib are not recommended in lung NETs, whereas sunitinib in nonpancreatic NETs should be restricted to clinical trials. 50 Although phase III clinical data on PRRT in TCs and ACs are not available, the preliminary efficacy findings of the phase III NETTER-1 trial indicated that 177 Lu-DOTATATE significantly prolonged median PFS compared with octreotide in patients with advanced midgut NETs. 62 In the advanced TC or AC setting, a recent phase II trial (n ¼ 34) demonstrated the antitumor activity of 177 Lu-DOTATATE in patients with progressive, metastatic TCs or ACs. After a median follow-up of 29 months, differences in outcomes were observed between patients with TCs and those with ACs in terms of disease control rates (80% versus 47%) and median PFS (20.1 versus 15.7 months). 63 As a result, phase III studies are warranted.
Trials in Progress
A number of ongoing clinical trials are currently under way to investigate the role of numerous promising systemic therapies in advanced well-differentiated NETs, including in patients with lung carcinoids (Table 3) . Primary results from the randomized, open-label, 3-arm, phase II LUNA trial, investigating the combination of everolimus plus pasireotide long-acting release with either agent alone in patients with well-differentiated lung or thymic NETs were presented in October 2016. The proportion of patients progression-free at month 9 was 39.0%, 33.3% and 58.5% for pasireotide long-acting release, everolimus and the drug combination, respectively. 64 An open-label, expanded access, phase IV study is also under way to assess the safety and efficacy of everolimus and the quality of life it provides in patients with advanced NETs of GI or lung origin. The randomized, double-blind, placebocontrolled, phase III SPINET trial will evaluate the efficacy and safety of lanreotide Autogel/Depot (Ipsen Ltd, Slough, UK/Ipsen Biopharmaceuticals Inc., Basking Ridge, NJ) in patients with well-differentiated, metastatic/unresectable SSTR-positive TCs or ACs who are receiving best supportive care. This study will be the first to evaluate the role of SSAs in TCs and ACs; SSAs are an established antiproliferative therapy in well-differentiated GI NETs according to the PROMID and CLARINET phase 3 clinical trials. 51, 65 Lanreotide Autogel will also be evaluated in combination with temozolomide in the open-label, multicenter, phase II ATLANT trial in well-differentiated, advanced, progressive lung or thymus NETs.
Multidisciplinary Approach to the Management of Lung NETs
The diagnosis and management of lung NETs is complex owing to the nonspecificity of symptoms when present and heterogeneity of the disease, as well as owing to the lack of high-level clinical evidence. 7, 35 As a result, there is agreement between experts from ENETS, NCCN, and the European Society of Thoracic Surgeons that a multidisciplinary approach to care is required for the effective and efficient diagnosis and management of advanced lung NETs. 15, 35, 45, 50 It is recommended that care of patients with lung NETs be individualized through a multidisciplinary tumor board specializing in lung NETs/pulmonary carcinoids, which may involve multiple specialists, including surgeons, medical and radiation oncologists, pulmonologists, pathologists, endocrinologists, and interventional radiologists. 15, 35, 45, 50 The findings of accurate imaging and pathologic review should be discussed within the multidisciplinary tumor board for appropriate therapeutic decision making to identify treatment options (observation, surgery, and systemic therapy) and determine an optimal management approach. 35, 45, 50 A multidisciplinary approach comprises coordinated care delivery by a team of health care professionals from various specialties. 35, 66 Such an approach in other cancers, including gastroenteropancreatic NET, NSCLC, breast cancer, and esophageal cancer, have led to improvements in diagnosis/staging, treatment planning, compliance with evidence-based therapy, patient prognosis and satisfaction, and clinical outcomes. [67] [68] [69] [70] [71] However, the composition of multidisciplinary teams may vary substantially across regions, countries, and centers.
Conclusions
Debate and controversy remain in the diagnosis, classification, and choice of appropriate treatment regimens for lung NETs, particularly in the setting of TCs and ACs. A diagnosis of lung TC or AC may be delayed or a tumor may be misdiagnosed as another type of lung NET, such as SCLC, which can lead to delays in the implementation of appropriate treatment or the use of ineffective, aggressive treatment approaches that have no clear benefit in TCs and ACs. These patients may be at risk for disease progression and associated reduced quality of life owing to excessive treatment-related toxicity.
The availability of effective treatment options for patients with advanced/metastatic lung NETs, particularly those with TCs or ACs, have previously been limited. RADIANT-4, the first phase III trial comprising a large subgroup of patients with lung NETs, recently reported a PFS benefit with everolimus in welldifferentiated lung NETs, resulting in its approval by the FDA as the first treatment for adult patients with advanced, well-differentiated, nonfunctional lung NETs. A number of ongoing trials investigating various therapy options for lung NETs are currently under way. Guidelines on lung NETs should be updated regularly as clinical data from these trials become available to ensure consensus between guideline recommendations, thus allowing for consistent and optimal levels of care.
In summary, there is a critical need to address issues surrounding the classification, diagnosis, and treatment of lung NETs. Increasing the awareness of this rare form of lung cancer is also needed among health care professionals, particularly thoracic specialists, who are often involved in the diagnosis and early treatment of patients with lung NET. Furthermore, the implementation of multidisciplinary care teams is an important aspect of lung NET management, and it has the potential to improve patient outcomes. Additional, adequately powered, active-comparator or placebo-controlled clinical trials are required in the lung NET subpopulation to provide evidence supporting treatment of this underserved type of NET.
